Table 4 Open in new tab Summary of...

Type of cancer

Trial name

Test arm

Control arm

Phase

Resource

Advanced NSCLC

LUNAR or EF‐24

TTFields with docetaxel or anti‐PD‐1

Docetaxel or anti‐PD‐1

III

ClinicalTrials.gov

107th AACR, 2017

ASCO, 2016

NovoCure Ltd

Recurrent ovarian cancer

INNOVATE‐3

TTFields with weekly paclitaxel

Paclitaxel

III

107th AACR, 2017

NovoCure Ltd

ASCO, 2018

Unresectable pancreatic cancer

PANOVA‐3

TTFields with gemcitabine plus nab‐paclitaxel

Gemcitabine plus nab‐paclitaxel

III

ClinicalTrials.gov

107th AACR, 2017

NovoCure Ltd

1‐5 brain metastasis from NSCLC

COMIT

TTFields

N/A

ClinicalTrials.gov

NovoCure Ltd

1‐10 brain metastasis from NSCLC

METIS

TTFields

Supportive care

III

ClinicalTrials.gov

107th AACR, 2017

NovoCure Ltd

Pediatric recurrent HGG or ependymoma

N/A

TTFields

N/A

ClinicalTrials.gov

107th AACR, 2017

Prevention of brain metastasis for SCLC

N/A

TTFields

N/A

ClinicalTrials.gov

Advanced hepatocellular carcinoma

HEPANOVA

TTFields with sorafinib

N/A

ClinicalTrials.gov

NovoCure Ltd

108th AACR, 2018

SCLC with brain metastasis

N/A

Stereotactic radiosurgery with TTFields

N/A

ClinicalTrials.gov

Bevacizumab‐naive, recurrent glioblastoma

N/A

TTFields with nivolumab ± ipilimumab

N/A

ClinicalTrials.gov

Newly diagnosed GBM

2‐THE‐TOP

Adjuvant TTFields with temozolomide and pembrolizumab

N/A

ClinicalTrials.gov

Newly diagnosed GBM

N/A

Concurrent TTFields with temozolomide and radiation

N/A

I/II

ClinicalTrials.gov

2018 Neuro‐Oncology Annual Meeting

Recurrent or progressive meningioma

N/A

TTFields with concurrent bevacizumab

N/A

ClinicalTrials.gov

High risk oligodendroglioma

N/A

TTFields

N/A

ClinicalTrials.gov

Table 4

Open in new tab

Summary of ongoing clinical trials on application of TTFields for solid malignancies

Type of cancer	Trial name	Test arm	Control arm	Phase	Resource
Advanced NSCLC	LUNAR or EF‐24	TTFields with docetaxel or anti‐PD‐1	Docetaxel or anti‐PD‐1	III	ClinicalTrials.gov 107th AACR, 2017 ASCO, 2016 NovoCure Ltd
Recurrent ovarian cancer	INNOVATE‐3	TTFields with weekly paclitaxel	Paclitaxel	III	107th AACR, 2017 NovoCure Ltd ASCO, 2018
Unresectable pancreatic cancer	PANOVA‐3	TTFields with gemcitabine plus nab‐paclitaxel	Gemcitabine plus nab‐paclitaxel	III	ClinicalTrials.gov 107th AACR, 2017 NovoCure Ltd
1‐5 brain metastasis from NSCLC	COMIT	TTFields	N/A	II	ClinicalTrials.gov NovoCure Ltd
1‐10 brain metastasis from NSCLC	METIS	TTFields	Supportive care	III	ClinicalTrials.gov 107th AACR, 2017 NovoCure Ltd
Pediatric recurrent HGG or ependymoma	N/A	TTFields	N/A	II	ClinicalTrials.gov 107th AACR, 2017
Prevention of brain metastasis for SCLC	N/A	TTFields	N/A	II	ClinicalTrials.gov
Advanced hepatocellular carcinoma	HEPANOVA	TTFields with sorafinib	N/A	II	ClinicalTrials.gov NovoCure Ltd 108th AACR, 2018
SCLC with brain metastasis	N/A	Stereotactic radiosurgery with TTFields	N/A	II	ClinicalTrials.gov
Bevacizumab‐naive, recurrent glioblastoma	N/A	TTFields with nivolumab ± ipilimumab	N/A	II	ClinicalTrials.gov
Newly diagnosed GBM	2‐THE‐TOP	Adjuvant TTFields with temozolomide and pembrolizumab	N/A	II	ClinicalTrials.gov
Newly diagnosed GBM	N/A	Concurrent TTFields with temozolomide and radiation	N/A	I/II	ClinicalTrials.gov 2018 Neuro‐Oncology Annual Meeting
Recurrent or progressive meningioma	N/A	TTFields with concurrent bevacizumab	N/A	II	ClinicalTrials.gov
High risk oligodendroglioma	N/A	TTFields	N/A	II	ClinicalTrials.gov

Type of cancer	Trial name	Test arm	Control arm	Phase	Resource
Advanced NSCLC	LUNAR or EF‐24	TTFields with docetaxel or anti‐PD‐1	Docetaxel or anti‐PD‐1	III	ClinicalTrials.gov 107th AACR, 2017 ASCO, 2016 NovoCure Ltd
Recurrent ovarian cancer	INNOVATE‐3	TTFields with weekly paclitaxel	Paclitaxel	III	107th AACR, 2017 NovoCure Ltd ASCO, 2018
Unresectable pancreatic cancer	PANOVA‐3	TTFields with gemcitabine plus nab‐paclitaxel	Gemcitabine plus nab‐paclitaxel	III	ClinicalTrials.gov 107th AACR, 2017 NovoCure Ltd
1‐5 brain metastasis from NSCLC	COMIT	TTFields	N/A	II	ClinicalTrials.gov NovoCure Ltd
1‐10 brain metastasis from NSCLC	METIS	TTFields	Supportive care	III	ClinicalTrials.gov 107th AACR, 2017 NovoCure Ltd
Pediatric recurrent HGG or ependymoma	N/A	TTFields	N/A	II	ClinicalTrials.gov 107th AACR, 2017
Prevention of brain metastasis for SCLC	N/A	TTFields	N/A	II	ClinicalTrials.gov
Advanced hepatocellular carcinoma	HEPANOVA	TTFields with sorafinib	N/A	II	ClinicalTrials.gov NovoCure Ltd 108th AACR, 2018
SCLC with brain metastasis	N/A	Stereotactic radiosurgery with TTFields	N/A	II	ClinicalTrials.gov
Bevacizumab‐naive, recurrent glioblastoma	N/A	TTFields with nivolumab ± ipilimumab	N/A	II	ClinicalTrials.gov
Newly diagnosed GBM	2‐THE‐TOP	Adjuvant TTFields with temozolomide and pembrolizumab	N/A	II	ClinicalTrials.gov
Newly diagnosed GBM	N/A	Concurrent TTFields with temozolomide and radiation	N/A	I/II	ClinicalTrials.gov 2018 Neuro‐Oncology Annual Meeting
Recurrent or progressive meningioma	N/A	TTFields with concurrent bevacizumab	N/A	II	ClinicalTrials.gov
High risk oligodendroglioma	N/A	TTFields	N/A	II	ClinicalTrials.gov

Abbreviations: AACR, American Association for Cancer Research annual meeting; ASCO, American Society for Clinical Oncology annual meeting; TTFields, tumor‐treating fields; HGG, high‐grade glioma; GBM, glioblastoma; N/A, not available; NSCLC, non‐small cell lung cancer; SCLC, small cell lung cancer.

This Feature Is Available To Subscribers Only